Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7719685 | 0.92 | KDM4E (0.42) | NAMPTNPC1RAB9AEPHX2L3MBTL1 | |
| SCHEMBL7724191 | 0.88 | KDM4E (0.50) | NPC1RAB9AEPHX2L3MBTL1CYP3A4 | |
| SCHEMBL7723034 | 0.84 | DAGLB (0.46) | NAMPTEPHX2KDM4E | |
| SCHEMBL7722987 | 0.84 | NAMPT (0.45) | NAMPTNPC1RAB9AEPHX2L3MBTL1 | |
| SCHEMBL7723042 | 0.82 | SMN1; SMN2 (0.51) | NPC1RAB9AEPHX2L3MBTL1SMN1; SMN2 | |
| SCHEMBL7729354 | 0.81 | NAMPT (0.50) | NAMPTNPC1RAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL7724193 | 0.81 | SMN1; SMN2 (0.56) | NAMPTNPC1RAB9ACYP3A4ALDH1A1 | |
| SCHEMBL7724226 | 0.77 | EPHX2 (0.57) | NPC1RAB9AEPHX2CYP3A4ALDH1A1 | |
| SCHEMBL7723097 | 0.77 | HSD17B10 (0.42) | NAMPTRAB9AEPHX2L3MBTL1CYP3A4 | |
| SCHEMBL1677824 | 0.77 | NAAA (0.48) | NAMPTNPC1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420398-B2 | FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-11-15 | — | — | US | disclosed |
| EP-1103543-A1 | NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | TNF, UACA, HRH4 | NAMPT 3320/4885NPC1 3850/4885RAB9A 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.